MSPrecise: A molecular diagnostic test for multiple sclerosis using next generation sequencing.

BACKGROUND We have previously demonstrated that cerebrospinal fluid-derived B cells from early relapsing-remitting multiple sclerosis (RRMS) patients that express a VH4 gene accumulate specific replacement mutations. These mutations can be quantified as a score that identifies such patients as having or likely to convert to RRMS. Furthermore, we showed that next generation sequencing is an efficient method for obtaining the sequencing information required by this mutation scoring tool, originally developed using the less clinically viable single-cell Sanger sequencing. OBJECTIVE To determine the accuracy of MSPrecise, the diagnostic test that identifies the presence of the RRMS-enriched mutation pattern from patient cerebrospinal fluid B cells. METHODS Cerebrospinal fluid cell pellets were obtained from RRMS and other neurological disease (OND) patient cohorts. VH4 gene segments were amplified, sequenced by next generation sequencing and analyzed for mutation score. RESULTS The diagnostic test showed a sensitivity of 75% on the RRMS cohort and a specificity of 88% on the OND cohort. The accuracy of the test in identifying RRMS patients or patients that will develop RRMS is 84%. CONCLUSION MSPrecise exhibits good performance in identifying patients with RRMS irrespective of time with RRMS.

[1]  J. Bennett,et al.  Potential of a unique antibody gene signature to predict conversion to clinically definite multiple sclerosis , 2009, Journal of Neuroimmunology.

[2]  M. Egholm,et al.  Measurement and Clinical Monitoring of Human Lymphocyte Clonality by Massively Parallel V-D-J Pyrosequencing , 2009, Science Translational Medicine.

[3]  Y. Qin,et al.  Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. , 1998, The Journal of clinical investigation.

[4]  E. Frohman,et al.  Cerebrospinal fluid B cells from multiple sclerosis patients are subject to normal germinal center selection , 2007, Journal of Neuroimmunology.

[5]  A. C. Kroksveen,et al.  Cerebrospinal fluid proteomics in multiple sclerosis. , 2015, Biochimica et biophysica acta.

[6]  E. Frohman,et al.  Antigen specificity of clonally expanded and receptor edited cerebrospinal fluid B cells from patients with relapsing remitting MS , 2007, Journal of Neuroimmunology.

[7]  D. Gilden,et al.  Single-Cell Repertoire Analysis Demonstrates that Clonal Expansion Is a Prominent Feature of the B Cell Response in Multiple Sclerosis Cerebrospinal Fluid 1 , 2003, The Journal of Immunology.

[8]  A. Bar-Or,et al.  Roles of immunoglobulins and B cells in multiple sclerosis: From pathogenesis to treatment , 2006, Journal of Neuroimmunology.

[9]  J. Bennett,et al.  Pharmacological properties, toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases. , 2007, CNS drug reviews.

[10]  Jeffrey A. Cohen,et al.  Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria , 2011, Annals of neurology.

[11]  Lindsay G. Cowell,et al.  The Antibody Genetics of Multiple Sclerosis: Comparing Next-Generation Sequencing to Sanger Sequencing , 2014, Front. Neurol..

[12]  S. Baranzini,et al.  B cell repertoire diversity and clonal expansion in multiple sclerosis brain lesions. , 1999, Journal of immunology.

[13]  N. Chiorazzi,et al.  Accumulation of Clonally Related B Lymphocytes in the Cerebrospinal Fluid of Multiple Sclerosis Patients1 , 2000, The Journal of Immunology.

[14]  E. Frohman,et al.  Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis. , 2005, Archives of neurology.

[15]  R. Brezinschek,et al.  Analysis of the heavy chain repertoire of human peripheral B cells using single-cell polymerase chain reaction. , 1995, Journal of immunology.

[16]  J. Bennett,et al.  VH4 Gene Segments Dominate the Intrathecal Humoral Immune Response in Multiple Sclerosis1 , 2007, The Journal of Immunology.

[17]  D. Arnold,et al.  B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. , 2008, The New England journal of medicine.

[18]  A. Bar-Or,et al.  Dynamics of B-Cell Populations in CSF and Blood in Patients Treated with a Combination of Rituximab and Mitoxantrone , 2013, ISRN neurology.

[19]  G. Bernardi,et al.  Cerebrospinal fluid in the diagnosis of multiple sclerosis: a consensus report. , 1994, Journal of neurology, neurosurgery, and psychiatry.

[20]  H. von Büdingen,et al.  Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin‐specific antibodies , 2008, European journal of immunology.

[21]  R. Brezinschek,et al.  Receptor revision and atypical mutational characteristics in clonally expanded B cells from the cerebrospinal fluid of recently diagnosed multiple sclerosis patients , 2005, Journal of Neuroimmunology.

[22]  D. Cox,et al.  B cell exchange across the blood-brain barrier in multiple sclerosis. , 2012, The Journal of clinical investigation.

[23]  J. Bennett,et al.  CSF IgG heavy-chain bias in patients at the time of a clinically isolated syndrome , 2008, Journal of Neuroimmunology.

[24]  D. Gilden,et al.  Restricted use of VH4 Germline segments in an acute multiple sclerosis brain , 1998, Annals of neurology.

[25]  F. Barkhof,et al.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial , 2011, The Lancet.

[26]  M. Krumbholz,et al.  B cells and antibodies in multiple sclerosis pathogenesis and therapy , 2012, Nature Reviews Neurology.